AMLX - IQ FUTU and VYNT among pre market losers

Arcadia Biosciences (RKDA) -25% on Q4 results. UiPath (PATH) -19% on Q4 results. Clarus Therapeutics (CRXT) -18% on Q4 results. Sharecare (SHCR) -15% on Q4 results. InflaRx (IFRX) -13% vilobelimab fails to show statistical significance in severe COVID patients in trial. Amylyx Pharmaceuticals (AMLX) -13% on FY results. iQIYI, Inc. (IQ) -11% provides update on its status under the Holding Foreign Companies Accountable Act. Vyant Bio (VYNT) -9%. Lottery.com (LTRY) -8% on Q4 results. Indonesia Energy (INDO) -8%. U.S. Well Services (USWS) -7% on Q4 results. Houston American Energy (HUSA) -7%. Nine Energy Service (NINE) -6%. Guardforce (GFAI) -6%. on FY results. Futu Holdings (FUTU) -5%. Tempur Sealy International (TPX) -5% foresees Q1 revenue below consensus.

For further details see:

IQ, FUTU and VYNT among pre market losers